Investment Thesis
ADC Therapeutics exhibits severe fundamental distress with negative stockholders' equity (-$216.4M) and persistent cash burn (-$29.7M operating FCF), indicating the company is technically insolvent on a balance sheet basis. While revenue is growing (+14.9% YoY) and losses are improving, the company is not yet viable as a standalone entity without additional financing or dramatic operational improvement.
Strengths
- Revenue growth of 14.9% YoY demonstrates commercial traction and product adoption
- EPS losses improving 30.9% YoY indicates operational efficiency gains and progress toward breakeven
- Strong cash position of $231M and excellent liquidity ratios (4.09x current) provide ~7-8 year runway at current burn rate
Risks
- Negative stockholders' equity of -$216.4M: liabilities exceed assets, indicating technical insolvency and extreme financial distress
- Persistent negative operating cash flow (-$29.7M) means company must rely on cash reserves; not self-sustaining without profitability achievement
- Operating margin of -121% and net margin of -158% show company spends $2.58 to generate $1 of revenue; path to profitability unclear
Key Metrics to Watch
- Operating cash flow trend: must turn positive within 24 months for viability
- Revenue growth acceleration and gross margin realization as sales scale
- Stockholders' equity trajectory: negative equity must reverse through sustained profitability or external financing
Financial Metrics
Revenue
20.9M
Net Income
-33.0M
EPS (Diluted)
$-0.21
Free Cash Flow
-29.7M
Total Assets
291.5M
Cash
231.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-121.1%
Net Margin
-158.1%
ROE
N/A
ROA
-11.3%
FCF Margin
-142.6%
Balance Sheet & Liquidity
Current Ratio
4.09x
Quick Ratio
4.02x
Debt/Equity
N/A
Debt/Assets
174.2%
Interest Coverage
-1.55x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T19:56:00.165170 |
Data as of: 2026-03-31 |
Powered by Claude AI